ArticleCell cycle (Georgetown, Tex.)2014

Evidence for eIF2α phosphorylation-independent effects of GSK2656157, a novel catalytic inhibitor of PERK with clinical implications.

Jothilatha Krishnamoorthy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.